Vista Investment Partners LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 674 shares of the medical research company’s stock, valued at approximately $211,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. International Assets Investment Management LLC bought a new position in Amgen in the 4th quarter worth $32,880,000. Tennessee Valley Asset Management Partners bought a new position in Amgen in the 4th quarter worth $79,000. TRUE Private Wealth Advisors raised its holdings in Amgen by 38.5% in the 4th quarter. TRUE Private Wealth Advisors now owns 2,567 shares of the medical research company’s stock worth $739,000 after purchasing an additional 714 shares in the last quarter. Oakworth Capital Inc. raised its holdings in Amgen by 101.5% in the 4th quarter. Oakworth Capital Inc. now owns 1,445 shares of the medical research company’s stock worth $416,000 after purchasing an additional 728 shares in the last quarter. Finally, Groesbeck Investment Management Corp NJ raised its holdings in Amgen by 5.6% in the 4th quarter. Groesbeck Investment Management Corp NJ now owns 3,788 shares of the medical research company’s stock worth $1,091,000 after purchasing an additional 200 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.
Amgen Stock Performance
Shares of NASDAQ AMGN traded down $1.69 during trading on Friday, reaching $321.44. 1,442,483 shares of the company traded hands, compared to its average volume of 2,616,239. The firm has a 50 day simple moving average of $319.99 and a 200-day simple moving average of $299.24. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The stock has a market capitalization of $172.43 billion, a PE ratio of 45.92, a P/E/G ratio of 2.78 and a beta of 0.58. Amgen Inc. has a 52-week low of $248.38 and a 52-week high of $346.85.
Amgen Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Friday, August 16th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. The ex-dividend date of this dividend is Friday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.
Analyst Upgrades and Downgrades
Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $230.00 to $300.00 in a research report on Friday, May 3rd. TD Cowen upped their target price on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Royal Bank of Canada upped their target price on shares of Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley reduced their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 11th. Eleven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $326.89.
Read Our Latest Stock Report on AMGN
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
- Five stocks we like better than Amgen
- What is a Stock Market Index and How Do You Use Them?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What is a Secondary Public Offering? What Investors Need to Know
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Use the MarketBeat Stock Screener
- MarketBeat Week in Review – 8/12 – 8/16
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.